Free tool
FAERS Monitor: Tribenzor
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200175 or its brand name (Tribenzor, Amlodipine Besylate, Hydrochlorothiazide, Olmesartan Medoxomil). Reports on generic versions are filed under their own applications.
Reports
1,244
Serious
713
57% of reports
Hospitalization
452
Death reported
34
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sprue-like enteropathy231
- gastrooesophageal reflux disease141
- acute kidney injury105
- weight decreased105
- diarrhoea104
- dizziness104
- constipation77
- haemorrhoids76
- chronic kidney disease72
- nausea67
- fatigue66
- large intestine polyp60
- drug ineffective57
- headache54
- hypotension53
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 2 |
| 2011 | 31 |
| 2012 | 47 |
| 2013 | 72 |
| 2014 | 79 |
| 2015 | 206 |
| 2016 | 216 |
| 2017 | 176 |
| 2018 | 208 |
| 2019 | 92 |
| 2020 | 27 |
| 2021 | 15 |
| 2022 | 17 |
| 2023 | 13 |
| 2024 | 11 |
| 2025 | 12 |
| 2026 | 20 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,915 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sprue-like enteropathySignal | 231 | 831.2 | 737.4 | 181,840 |
| large intestine polypSignal | 60 | 147.7 | 115.3 | 8,526 |
| haemorrhoidsSignal | 76 | 66.1 | 53.2 | 4,795 |
| gastrooesophageal reflux diseaseSignal | 141 | 29.7 | 25.4 | 3,885 |
| chronic kidney diseaseSignal | 72 | 16.0 | 12.8 | 1,003 |
| acute kidney injurySignal | 105 | 11.6 | 9.7 | 1,014 |
| weight decreasedSignal | 105 | 6.4 | 5.3 | 475 |
| constipationSignal | 77 | 6.0 | 4.8 | 317 |
| hypotensionSignal | 53 | 4.5 | 3.4 | 141 |
| dizzinessSignal | 104 | 3.5 | 2.9 | 190 |
| diarrhoeaSignal | 104 | 2.7 | 2.3 | 115 |
| headache | 54 | 1.5 | 1.1 | 7 |
| fatigue | 66 | 1.4 | 1.1 | 9 |
| nausea | 67 | 1.4 | 1.1 | 9 |
| drug ineffective | 57 | 0.7 | 0.6 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.